AIM-HI Accelerator Fund shared a post on LinkedIn:
“Congratulations to the 2026 AIM-HI Venture Competition Semi-Finalists!
These seven pioneering companies have emerged with bold ideas and breakthrough technologies aimed at transforming the future of oncology (listed in alphabetical order):
- Cellinfinity Bio
- Nemea Therapeutics
- RedPoint Oncology, Inc
- Resolute Science
- Talus Bio
- Trojan Bio
- VerImmune
AIM-HI is proud to support visionary scientist-entrepreneurs by connecting them with funding opportunities, expert mentorship, and a global network of oncology innovation leaders accelerating the path from breakthrough science to treatments that reach patients.
Learn more about the competition.”
Other articles about AIM-HI Accelerator Fund on OncoDaily,